Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tagraxofusp
- Development stage
- Approved
- Lead developer
- Stemline Therapeutics
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Tagraxofusp is a CD123-directed cytotoxin and recombinant fusion protein composed of human interleukin-3 (IL-3) genetically fused to the catalytic and translocation domains of truncated diphtheria toxin. It is used for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematologic malignancy. Tagraxofusp binds with high affinity to the IL-3 receptor alpha chain (CD123) on target cells, is internalized via receptor-mediated endocytosis, and releases its diphtheria toxin component into the cytosol. The toxin irreversibly inhibits protein synthesis by inactivating elongation factor 2, leading to apoptosis of malignant cells. Tagraxofusp was first approved by the FDA in December 2018 as the first treatment for BPDCN and later received approval in Europe[2][4][5][7][8].
- Brand names
- Elzonris
- Other names
- tagraxofusp
02
Targets
EEF2 (Eukaryotic elongation factor 2)IL3RA (Interleukin 3 Receptor)
Beyond the preview
Go deeper on tagraxofusp.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tagraxofusp.